QLG Survivorship 4

  • Research type

    Research Study

  • Full title

    Phase IV Development of an EORTC QoL Cancer Survivorship Questionnaire and Three Site Specific Modules

  • IRAS ID

    315095

  • Contact name

    Mieke Van Hemelrijck

  • Contact email

    mieke.vanhemelrijck@kcl.ac.uk

  • Sponsor organisation

    King's College London

  • Duration of Study in the UK

    1 years, 6 months, 0 days

  • Research summary

    The European Organisation of Research and Treatment of Cancer’s Quality of Life Group (EORTC QLG) has developed a four-phase framework that can be used to develop and validate quality of life questionnaires for individuals with cancer. These are developed as modules to supplement their existing EORTC core quality of life questionnaire, the ‘QLQ-C30’. For example, modules have previously been developed for endometrial cancer (QLQEN24), bone metastases (QLQ-BM22), and cancer-related fatigue (QLQ-FA12). The four-phase approach comprises a literature review followed by interviews with patients and clinicians (Phase 1), construction of a questionnaire (Phase 2), refinement of the questionnaire (Phase 3), and finally administration of the questionnaire to an international sample in a full validation study (Phase 4).

    The present study aims to contribute to the development of a module designed to measure quality of life in cancer survivors (i.e. those that are >1 year post-diagnosis and have a good prognosis). The study aims to undertake Phase 4 of the above module development process.

  • REC name

    London - Camden & Kings Cross Research Ethics Committee

  • REC reference

    22/LO/0491

  • Date of REC Opinion

    4 Aug 2022

  • REC opinion

    Further Information Favourable Opinion